Situation

GRA worked in partnership with a European vaccine development company to lead an application for a £1 million SBRI contract funded by the UK’s Department of Health.  The funds were intended for the clinical and formulation development of a Zika vaccine.

GRA Involvement

• Scoping of Zika vaccine business case
• Led application for government based funding
• Development of Zika clinical project plan
• Interaction with UK’s SBRI

Value Added

GRA worked with the vaccine company to assemble a business case for the development of a Zika vaccine and justify how the funding could accelerate their program into phase I clinical trials.  This case was put forward to the SBRI review panel.  The application was described as ‘exemplary’ by the review panel and after a final interview panel, the application was confirmed as successful in June 2016.   The project is being performed over a period of 18 months.  GRA successfully helped lead the application to raise almost £1 million in non-dilutional funding to develop the vaccine.  GRA is also project managing the contract.  Read the press release here.